Search Results 21-30 of 77 for ⏳정품슬롯 【위너보증.com / 가입코드 9122】 라칸 ⏳

  1. Px Code,Supply #,Description,Unit Price 278000026,3643,KIT HEMODIALYSIS CATHETER POLYURETHANE DUAL LUMEN OVER THE WIRE SYMMETRIC TIP 14.5FRX19CM,498.12 ...

  2. Px Code,Supply #,Description,Unit Price 278000024,48589,CATH ABL THRMCL ST FJ,"5,504.00" 278000025,55648,CATH ABL CLS NON-NAV 6FX4,"1,312.00" 278000026 ...

  3. https://www.mayoclinic.org/arabic_patient_consumer_web.xml

  4. Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer - Mayo Clinic

    About this study. This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with ...

  5. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery - Mayo Clinic

    About this study. This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other ...

  6. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Giving ixazomib with pomalidomide and dexamethasone may be an effective treatment for relapsed or relapsed/refractory multiple myeloma. Participation ...

  7. Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors - Mayo Clinic

    Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors need to grow. Studying samples of blood in the laboratory from patients ...

  8. A Study to Evaluate the Safety and Tolerability of DCC-2618 in Patients with Advanced Malignancies - Mayo Clinic

    This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics ...

  9. A Study to Investigate the Safety and Effectiveness of FE 999049 in Controlled Ovarian Stimulation in Women Aged 35-42 Years Old - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  10. Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer - Mayo Clinic

    Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Binimetinib may stop the growth of tumor ...